Morning Watch List: ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), Frontier Communications Corporation (NASDAQ:FTR), Perrigo Company plc (NYSE:PRGO), Green Plains (NASDAQ:GPRE), Ligand Pharmaceuticals (NASDAQ:LGND)

ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), announced that the first patient has been enrolled in the Company’s pivotal Phase 3 clinical study, study 007, of FV-100 to prevent the debilitating shingles-associated pain known as post-herpetic neuralgia (PHN). The first patient in the study enrolled at Center for Clinical Studies in Houston, Texas. The study will build upon prior clinical results for FV-100, including Phase 1 trials and a large Phase 2 clinical trial in shingles patients, which demonstrated favorable safety and tolerability for FV-100. ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) belongs to Healthcare sector. Its weekly performance is 8.41%. On last trading day company shares ended up $4.90. ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) distance from 50-day simple moving average (SMA50) is 6.52%.

Frontier Communications Corporation (NASDAQ:FTR) on Monday reported a second-quarter loss of $28 million, after reporting a profit in the same period a year earlier.On a per-share basis, the Stamford, Connecticut-based company said it had a loss of 3 cents. Earnings, adjusted for one-time gains and costs, were 3 cents per share. Frontier Communications Corporation (NASDAQ:FTR) shares increased 1.94% in last trading session and ended the day at $5.25. FTR Gross Margin is 60.80% and its return on assets is 0.20%. Frontier Communications Corporation (NASDAQ:FTR) quarterly performance is -20.49%.

Perrigo Company plc Ordinary Shares (NYSE:PRGO) has entered into an agreement for the acquisition of Naturwohl Pharma GmbH along with its leading German dietary supplement brand, Yokebe. The deal, slated to close in the third quarter of 2015, is expected to be accretive to the company’s calendar 2015 adjusted earnings per share and exceed its ROIC threshold in calendar year 2016. On 04 August, Perrigo Company plc Ordinary Shares (NYSE:PRGO) shares moved down -0.97% and was closed at $190.64. PRGO EPS growth in last 5 year was 3.10%. Perrigo Company plc Ordinary Shares (NYSE:PRGO) year to date (YTD) performance is 14.21%.

Green Plains Inc. (NASDAQ:GPRE) is courting Mexican fuel buyers in a bid to boost ethanol exports to the country, the company said on Wednesday, as the U.S. industry continues its search for new outlets for growing output and large supplies.Green Plains has had discussions with industrial users in Mexico to sell U.S. ethanol, the Omaha, Nebraska, ethanol producer’s president and chief executive officer, Todd Becker, told Reuters in an interview after an investor call.Green Plains Inc. (NASDAQ:GPRE) ended the last trading day at $21.09. Company weekly volatility is calculated as 7.56% and price to cash ratio as 1.97. Green Plains Inc. (NASDAQ:GPRE) showed a weekly performance of -10.82%.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the appointment of Matthew Korenberg as Vice President, Finance and Chief Financial Officer. Mr. Korenberg is expected to join Ligand’s management team on August 6th. Mr. Korenberg joins Ligand from NeuroCircuit Therapeutics, a developer of drugs to treat genetic disorders affecting the brain including Down syndrome, where he was founder and Chief Executive Officer. Prior to NeuroCircuit Therapeutics, Mr. Korenberg was with Goldman, Sachs & Co. for 14 years in the firm’s New York, London and San Francisco offices. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) shares increased 0.52% in last trading session and ended the day at $109.31. LGND Gross Margin is 87.70% and its return on assets is 5.70%. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) quarterly performance is 40.74%.

Leave a Reply

Your email address will not be published. Required fields are marked *